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Less is more when it comes  
to ketorolac for pain
It’s time to review our dosing with ketorolac for acute 
pain management. 
PRACTICE CHANGER
Use a low dose (10 mg) of intravenous 
ketorolac for moderate to severe acute pain 
in adults because it is as effective as higher 
doses (15-30 mg).1 
STRENGTH OF RECOMMENDATION
B: Based on a single, good-quality random-
ized controlled trial.
Motov S, Yasavolian M, Likourezos A, et al. Comparison of intravenous 
ketorolac at three single-dose regimens for treating acute pain in the 
emergency department: a randomized controlled trial. Ann Emerg 
Med. 2017;70:177-184.
ILLUSTRATIVE CASE
A 46-year-old man with no significant past 
medical history presents to the emergency 
department (ED) with right flank pain and 
nausea. A computed tomography scan reveals 
a 5-mm ureteral stone with no obstruction or 
hydronephrosis. You are planning on starting 
him on intravenous (IV) ketorolac for pain. 
What is the most appropriate dose? 
Ketorolac tromethamine is a highly effective nonsteroidal anti-inflam-matory drug (NSAID). As a non-
opiate analgesic, it is often the optimal first 
choice for the treatment of acute condi-
tions such as flank, abdominal, musculo-
skeletal, and headache pains.2 While it is 
not associated with euphoria, withdrawal 
effects, or respiratory depression (like its 
opiate analgesic counterparts), ketorolac 
carries a US Food and Drug Administra-
tion black box warning for gastrointestinal, 
cardiovascular, renal, and bleeding risks.3 
NSAIDs are known to have a “ceiling dose,” 
a dose at which maximum analgesic benefit is 
achieved; higher doses will not provide further 
pain relief. Higher doses of ketorolac may be 
used when anti-inflammatory effects of NSAIDs 
are desired, but they are likely to cause more 
adverse effects.4 Available data describe the an-
algesic ceiling dose of ketorolac as 10 mg across 
dosage forms.4,5 Yet, the majority of research and 
the majority of health care providers in current 
practice use higher doses of 20 to 60 mg. The 
US Food and Drug Administration label pro-
vides for a maximum dose of 60 mg/d.3 
In one recent study, ketorolac was pre-
scribed above its ceiling dose of 10 mg in at 
least 97% of patients who received IV doses and 
in at least 96% of patients receiving intramuscu-
lar (IM) doses in a US emergency department.6 
If ketorolac 10 mg is an effective analgesic dose, 
current practice exceeds the label recommen-
dation to use the lowest effective dose. This 
study sought to determine the comparative 
efficacy of 3 different doses of IV ketorolac for 
acute pain management in an ED.
STUDY SUMMARY
Though often used at higher doses,  
10 mg of ketorolac is enough for pain
This randomized double-blind trial evaluated 
the effectiveness of 3 different doses of IV ke-
torolac for acute pain in 240 adult patients, ages 
18 to 65 years, presenting to an ED with acute 
flank, abdominal, musculoskeletal, or headache 
pain.1 Acute pain was defined as onset ≤30 days. 
Patients were randomized to receive either 
10, 15, or 30 mg of IV ketorolac in 10 mL of nor-
mal saline. A pharmacist prepared the medica-
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tion in identical syringes, and the syringes were 
delivered in a blinded manner to the nurses car-
ing for the patients. Pain (measured using a 0 to 
10 scale), vital signs, and adverse effects were as-
sessed at baseline and at 15, 30, 60, 90, and 120 
minutes. If patients were still in pain at 30 min-
utes, IV morphine 0.1 mg/kg was offered. The 
primary outcome was numerical pain score at 
30 minutes after ketorolac administration; sec-
ondary outcomes included the occurrence of 
adverse events and the use of rescue medication. 
The groups were similar in terms of demo-
graphics and baseline vital signs. The mean age 
of the participants was 39 to 42 years. Across the 
3 groups, 36% to 40% of patients had abdominal 
pain, 26% to 39% had flank pain, 20% to 26% had 
musculoskeletal pain, and 1% to 11% had head-
ache pain. Patients had pain for an average of 1.5 
to 3.5 days. 
Baseline pain scores were similar for all 
3 groups (7.5-7.8 on a 10-point scale). In the in-
tention-to-treat analysis, all 3 doses of ketorolac 
decreased pain significantly at 30 minutes, but 
there was no difference between the groups; 
for the 10- and 15-mg groups, the mean pain 
scores post-intervention were 5.1 (95% confi-
dence interval [CI] 4.5-5.7 and 4.5-5.6, respec-
tively); and for the 30-mg group, the mean pain 
score was 4.8 (95% CI, 4.2-5.5). No P values were 
provided. There was no difference between the 
groups at any other time intervals. There was 
also no difference in the number of patients 
who needed rescue medication (morphine) at 
30 minutes between the groups (4 patients in 
the 10-mg group, 3 patients in the 15-mg group, 
and 4 patients in the 30-mg group; no P values 
were provided). In addition, adverse events (eg, 
dizziness, nausea, headache, itching, flushing) 
did not differ between the groups.
WHAT’S NEW
10 mg is just as effective as 30 mg
This trial confirms that a low dose (10 mg) of 
IV ketorolac is just as effective for acute pain 
control as higher 15- and 30-mg doses. 
CAVEATS
A 2-hour time limit and no look 
at long-term effects
The ketorolac dose of 10 mg IV was specially 
prepared by the study pharmacist; it is un-
likely this will be readily available in clinical 
settings. However, the 15-mg IV dose is also 
as effective as the higher 30-mg dose based 
on study results and is readily available. 
It isn’t known whether the higher dose 
would have provided greater pain relief be-
yond the 120 minutes evaluated in this trial, 
or if alternative dosage forms (oral or IM) 
would result in different outcomes. This 
study was not designed to compare serious 
long-term adverse effects like bleeding, renal 
impairment, or cardiovascular events. Addi-
tionally, this study was not powered to look 
at specific therapeutic indications or anti-
inflammatory response. 
CHALLENGES TO IMPLEMENTATION
A 10-mg single-dose vial  
is not readily available
Ketorolac tromethamine for injection is avail-
able in the United States in 15-, 30-, and 60-
mg single-dose vials. Because a 10-mg dose 
is not available as a single-dose vial, it would 
need to be specially prepared. However, this 
study should reassure providers that using 
the lowest available dose (eg, 15 mg IV if that 
is what is available) will relieve acute pain as 
well as higher doses.                JFP
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